¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Colon cancer risk"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® breast cancer ÇÑ±Û À¯¹æ¾Ï
¼³¸í   
  À¯¹æÀº Áö¹æÁ¶Á÷°ú º»·¡ÀÇ ¸ñÀûÀΠÁ£À» »ý»êÇϴ »ùÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷¿¡¼­ »ý»êÇÑ Á£À» ¹Û¿¡±îÁö ³»º¸³»´Â °üÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ ÁÖÀ§¸¦ µÑ·¯½Î°í ÀÖÀ¸¸é¼­ À̰͵éÀÇ ¸ð¾çÀ» À¯ÁöÇØÁִ °£Áú·Î ÀÌ·ç¾îÁø´Ù. À¯¹æ¾ÏÀ̶õ »ùÁ¶Á÷°ú °üÁ¶Á÷¿¡¼­ ±â¿øÇϴ Á¾¾çÀ» ¸»ÇÑ´Ù.
  
  À¯¹æ¾ÏÀ» ¹ß»ý½Ãų ¼ö Àִ À§ÇèÀÎÀڴ ¿©·¯ °¡Áö°¡ ¹àÇôÁ® ÀÖ´Ù. ±×Áß¿¡¼­ ´ëÇ¥ÀûÀΠ°ÍÀº ´ÙÀ½°ú °°´Ù.
  
  1.À¯ÀüÀû ¿äÀΣ­°¡Á· Áß¿¡¼­ À¯¹æ¾Ï¿¡ °É¸° »ç¶÷ÀÌ ÀÖÀ¸¸é À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀÌ ¾ÆÁÖ ³ô¾ÆÁø´Ù.
  
  2.¿¡½ºÆ®·Î°Õ¿¡ Àå±âÀûÀ¸·Î ¸¹ÀÌ Æø·ÎµÇ´Â °æ¿ì£­¿¡½ºÆ®·Î°ÕÀº ¿©¼ºÈ£¸£¸óÀ¸·Î ¿©¼º¿¡¼­ Á¤»óÀûÀ¸·Î »ý¸®ÀÇ Áֱ⿡ µû¶ó Áõ°¨À» µÇÇ®ÀÌÇÑ´Ù. ÀÌ ¿¡½ºÆ®·Î°ÕÀº À¯¹æÀÇ Á¥»ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ Áõ½Ä°ú ¼ºÀå¿¡ °ü°èÇÑ´Ù. ±×¸®°í ÀÌ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·ÎµÇ´Â »ç¶÷Àº À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù. ¿ÜºÎ¿¡¼­ ¿¡½ºÆ®·Î°ÕÀÇ Á¦Á¦¸¦ Ä¡·á¸ñÀûÀ¸·Î Åõ¿©ÇÒ °æ¿ì¿¡ À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀº Á¤»óÀο¡¼­ º¸´Ù ÇöÀúÇϰԠ³ô¾ÆÁø´Ù. ±×¸®°í ¾ÆÀ̸¦ ³ºÁö ¾Ê°í Æò»ýÀ» »ç´Â ¿©ÀÚÀÇ °æ¿ì¿¡ ÀÓ½ÅÀ» ÇÏ°í ¾ÆÀ̸¦ ³ºÀº ¿©ÀÚ¿¡ ºñÇØ¼­ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·Î°¡ µÇ¹Ç·Î(ÀӽŽÿ¡´Â ºñÀӽŽú¸´Ù ¿¡½ºÆ®·Î°Õ¿¡ Àû°Ô Æø·Î°¡ µÈ´Ù)À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù.
  
  3.ȯ°æÀû ¿äÀΣ­Áö¹æÁú ¼·ÃëÀÇ Áõ°¡, ¼úÀÇ ¼·Ãë µîÀº À¯¹æ¾ÏÀÇ È®·üÀ» ³ôÀδÙ.
  
  À¯¹æ¾ÏÀÇ Áõ»óÀ¸·Î °¡Àå ¸¹Àº °ÍÀº ¾ÆÇÁÁö ¾ÊÀº À¯¹æÀÇ µ¢¾î¸®ÀÌ´Ù. ±×¸®°í À¯µÎ¿¡¼­ ºÐºñ¹°ÀÌ ³ª¿À°Å³ª, À¯¹æÀÇ ÇǺκ¯È­ µîÀÌ À¯¹æ¾ÏÀÇ ÈçÇÑ Áõ»óÀÌ´Ù.
  
  Ä¡·á´Â À¯¹æÀÇ ÀýÁ¦¼úÀÌ °¡Àå È¿°úÀûÀΠġ·á¹ýÀ¸·Î µÇ¾îÀÖ´Ù. ±×¸®°í À̰Ϳ¡ ´õÇÏ¿© ¹æ»ç¼± Ä¡·á³ª Ç×¾ÏÁ¦¿ä¹ýµµ È¿°ú°¡ Àִ °ÍÀ¸·Î µÇ¾îÀÖ´Ù. ¶Ç ¿¡½ºÆ®·Î°ÕÀÇ °úÀ×°ú °ü°è°¡ Àִ Á¾¾çÀÏ °æ¿ì¿¡´Â ¿¡½ºÆ®·Î°ÕÀÇ È¿°ú¸¦ Â÷´ÜÇϴ ¾à¹°µµ È¿°ú°¡ ÀÖ´Ù.
¿µ¹® cervix cancer ÇÑ±Û Àڱøñ¾Ï, ÀڱðæºÎ¾Ï
¼³¸í   
  ÀÚ±ÃÀÇ ¸ñÀº ÀÚ±ÃÀÌ Áú°ú ¿¬°áµÈ ºÎÀ§·Î ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇϴ ºÎÀ§ÀÌ´Ù. À̰÷ÀÇ »óÇǼ¼Æ÷¿¡¼­ ¹ß»ýÇϴ ¾ÏÀ» Àڱøñ¾ÏÀ̶ó°í ÇÑ´Ù.
  
  Àڱøñ¾ÏÀÇ ¹ß»ýÀ» »ìÆìº¸¸é ÀڱøñÀÇ »óÇǼ¼Æ÷°¡ ¿©·¯ °¡Áö Àڱؿ¡ ÀÇÇØ¼­ Á¤»ó¼¼Æ÷¿Í Â÷À̳ª´Â ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ »ý±â°Ô µÈ´Ù. ÀÌ ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷´Â Ã³À½¿¡´Â ÀڱøñÀÇ »óÇǼ¼Æ÷ÃþÀÇ ÀϺθ¦ ÀÌ·ç°í ÀÖ°Ô µÈ´Ù. ±×·¯´Ù°¡ Á¡Á¡ ´õ ÁøÇàÀÌ µÇ¸é ¾Ï¼º¼¼Æ÷°¡ Àڱøñ »óÇǼ¼Æ÷ÀÇ ¸ðµç ÃþÀ» ²Ëä¿ì°Ô µÈ´Ù. ±×¸®°í °è¼Ó ÁøÇàÇϸ頻óÇǼ¼Æ÷ÀÇ ¸Ç ¹Ø¿¡ Àִ ¹Ù´Ú¸·À» ¶Õ°í ¹öÆÀÁ¶Á÷À¸·Î Ä§À±ÇØ µé¾î°¡°Ô µÈ´Ù. ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀÇ ÀϺθ¦ Ã¤¿ì´Â °ÍÀ» ÀڱøñÇü¼ºÀÌ»ó(cervical dysplasia)¶ó°í ÇÏ°í ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀ» ¸ðµÎ Ã¤¿ö¹ö·Á Á¤»óÀûÀΠ¼¼Æ÷°¡ ¾ø´Â °æ¿ì¸¦ »óÇdz»¾ÏÁ¾(carcinoma in situ)¶ó°í ÇÑ´Ù. ±×¸®°í ¹Ù´Ú¸·À» ¶Õ°í ¹ØÀÇ ¹öÆÀÁ¶Á÷À¸·Î Ä§¹üÇØ ³ª°¡´Â °æ¿ì¸¦ Ä§À±¾Ï(invasive cancer)¶ó°í ÇÑ´Ù.
  
  Àڱøñ¾ÏÀº ¿©·¯ ¸íÀÇ »ó´ë¿Í ¼º°ü°è¸¦ °¡Áö´Â ¿©ÀÚ, ±×¸®°í Ã¹ ¼º°æÇèÀÇ ³ªÀ̰¡ ¾î¸° ¿©ÀÚ¿¡°Ô¼­ ÈçÇÏ°í ¶Ç »çȸÀû, °æÁ¦Àû ¼öÁØÀÌ ³·Àº »ç¶÷¿¡°Ô¼­ Àß °É¸®´Â °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ÀÌ·± °ÍÀ¸·Î ¹Ì·ç¾î Àڱøñ¼¼Æ÷ÀÇ ¾Ï¼ºº¯È­¿¡´Â ¼ºº´°ú °°Àº °¨¿°ÀÌ Áß¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ°í, ¶Ç ¸î°¡Áö ¹ÙÀÌ·¯½ºÀÇ °¨¿°ÀÌ Àڱøñ¾ÏÀÇ ¿øÀÎÀ̶ó´Â °ÍÀÌ ¹àÇôÁ® ÀÖ´Ù.
  
  Àڱøñ¾ÏÀÇ Áø´Ü¹æ¹ýÀ¸·Î´Â Áú¼¼Æ÷°Ë»ç, ÄÝÆ÷½ºÄÚÇÇ, »ý°Ë(biopsy) µîÀÌ ÀÖ´Ù. ¼¼Æ÷°Ë»ç¶õ Á¶±âÁø´Ü ¸ñÀûÀ¸·Î °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ¹ýÀ¸·Î ¼ØºÀÀ¸·Î ÀڱøñÀ»¸¦ ¹®Áú·¯¼­ Àڱøñ»óÇǼ¼Æ÷¸¦ ¾ò°í À̰ÍÀ» Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© »óÇǼ¼Æ÷ÀÇ º¯È­¸¦ º¸´Â °ÍÀÌ´Ù. ÄÝÆ÷½ºÄÚÇǶõ ÀÚ±ÃÀÇ ¸ñÀ» 4~10¹è Á¤µµ È®´ëÇØ¼­ º¸´Â ÀÏÁ¾ÀÇ È®´ë°æ°Ë»çÀ¸·Î Àڱøñ¾ÏÀ¸·Î ÀÎÇÑ ÀڱøñÀÇ º´Àûº¯È­¸¦ °üÂûÇÏ¿© Áø´ÜÇϴ °ÍÀÌ´Ù. »ý°Ë¶õ Áø´ÜÀ» À§Çؼ­ Á÷Á¢ ÀڱøñÀÇ Á¶Á÷À» ¶¼¾î Ã¤ÃëÇÏ¿© Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Áø´ÜÇϴ °ÍÀ¸·Î °¡Àå Á¤È®ÇÑ Áø´Ü¹ýÀÌ´Ù.
  
  Ä¡·á·Î´Â º´ÀÇ ÁøÇàÁ¤µµ¿¡ µû¶ó ´Ù¸£°ÚÁö¸¸ ¾ÏÀÇ ÁøÇàÀÌ °ÅÀÇ ¾ø¾î Çü¼ºÀÌ»óÀ̳ª Á¦ÀÚ¸®¾ÏÁ¾ ¶Ç´Â ¾ÆÁÖ Á¶±Ý Ä§À±ÇÏ¿´À» °æ¿ì¿¡´Â ¼ö¼úÀû¿ä¹ýÀ¸·Î ÀÚ±ÃÀ» ÀûÃâÇϴ °ÍÀÌ Ä¡·áÀÇ ¿øÄ¢ÀÌ°í ¸¹Àº ÁøÇàÀ» º¸¿© ´Ù¸¥ Á¶Á÷À¸·Î ¾ÏÀǠħÀ±ÀÌ ÀÖÀ» °æ¿ì¿¡´Â ¹æ»ç¼± Ä¡·á¸¦ ¿øÄ¢À¸·Î ÇÑ´Ù.
¿µ¹® advanced cancer ÇÑ±Û ÁøÇà¾Ï
¼³¸í   
  Á¶±â¾Ï¿¡ ´ëÇÑ ¸»·Î ¾ÏÀÇ °æ°ú°¡ ÁøÇàµÈ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® lung cancer ÇÑ±Û Æó¾Ï
¼³¸í   
  ÇãÆÄ¿¡ »ý±â´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. °¡Àå ¿¹Èİ¡ ³ª»Û Á¾¾çÁßÀÇ Çϳª·Î½á Á¶±â¹ß°ßÀÌ ¾î·Æ°í Áõ¼¼ ¶ÇÇÑ ´Ê°Ô ³ªÅ¸³ª¼­, ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£³ª Ä¡·áÈÄ¿¡µµ ´ë°³ 8%¸¸ÀÌ 5³â »ýÁ¸ÀÌ °¡´ÉÇÑ ¾Ç¼ºÁ¾¾çÀÌ´Ù. À¯¹ßÀÎÀڷδ ´ëÇ¥ÀûÀ¸·Î ´ã¹è°¡ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, À¯ÀüÀûÀΠ¿ä¼Òµµ ¾î´À Á¤µµ ±â¿©Çϴ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
¿µ¹® cancer chemotherapy ÇÑ±Û Ç×¾ÏÈ­Çпä¹ý
¼³¸í   
  È­ÇÐÀû ¹°ÁúÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» Ä¡·áÇϴ °ÍÀ» ¸»ÇÑ´Ù. À̶§ »ç¿ëµÇ´Â ¹°ÁúÀ» Ç×¾ÏÁ¦¶ó°í ÇÑ´Ù. ÀÌ»óÀûÀΠÇ×¾ÏÁ¦´Â Á¤»óÀûÀΠ¼¼Æ÷¿¡´Â ÀÌ»óÀÌ ¾ø°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀΠȿ°ú¸¦ ³ªÅ¸³»¾î¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀǠƯÀÌÇѠƯ¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇϴ ¾à¹°À» °³¹ßÇÏ¿©¾ß ÇÑ´Ù. ÃÖ±Ù ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â(DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼­ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡¼­´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼­µµ Á¤»óÀûÀ¸·Î Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒÈ­°üÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ÀÌ·± ¼¼Æ÷°¡ ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î Ä¡¸íÀûÀΠ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼­ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒÈ­ºÒ·®ÀÌ À߿´Ù).
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low risk group
    ÀúÀ§Ç豺
  • physical hazard risk
    ¹°¸®ÀûÀ¯ÇØÀ§Çèµµ
  • population attributable risk
    ¸ðÁý´Ü±âÀÎÀ§Çèµµ
  • relative risk
    »ó´ëÀ§Çèµµ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • radiation risk coefficient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • risk
    1. À§Çè 2. À§Çèµµ
  • risk assessment
    À§ÇèµµÆò°¡
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • risk factor
    À§ÇèÀÎÀÚ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§ÇèÇ¥ÁöÀÚ
  • risk ratio
    À§Çèºñ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bladder cancer
    ¹æ±¤¾Ï
  • cervical cancer
    Àڱøñ¾Ï, ÀڱðæºÎ¾Ï
  • follicular cancer
    ¼ÒÆ÷¾Ï
  • gallbladder cancer
    ¾µ°³¾Ï
  • infiltrating cancer
    ħÀ±¾Ï
  • inflammatory breast cancer
    ¿°ÁõÀ¯¹æ¾Ï
  • medullary cancer
    ¼ÓÁú¾Ï, ¼öÁú¾Ï
  • metastatic cancer
    ÀüÀ̾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • prostatic cancer
    Àü¸³»ù¾Ï
  • renal cancer
    ÄáÆÏ¾Ï, ½ÅÀå¾Ï
  • thyroid papillary cancer
    °©»ó»ùÀ¯µÎ¾ÏÁ¾
  • undifferentiated cancer
    ¹ÌºÐÈ­¾Ï
  • cancer pain
    ¾ÏÅëÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • corset cancer
    ÄÚ¸£¼Â¾Ï
  • duct cancer
    (¢¡duct carcinoma) °ü¾ÏÁ¾
  • early cancer
    Á¶±â¾Ï
  • infiltrating cancer
    ħÀ±¾Ï
  • metastatic cancer
    ÀüÀ̾Ï
  • occult cancer
    ÀáÀç¾Ï
  • occupational cancer
    Á÷¾÷¾Ï
  • papillary cancer
    À¯µÎ¸ð¾ç¾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • radiation-induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • recurrent cancer
    Àç¹ß¾Ï
  • retrograde cancer
    ÅðÇà¾Ï
  • small cell lung cancer
    ÀÛÀº¼¼Æ÷ÇãÆÄ¾Ï, ¼Ò¼¼Æ÷Æó¾Ï
  • soft cancer
    (¢¡medullary carcinoma) ¼ÓÁú¾ÏÁ¾, ¼öÁú¾ÏÁ¾
  • solid cancer
    °íÇü¾Ï
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary cancer
    ¿ø¹ß¾Ï(ê«Û¡äß)
  • prostatic cancer
    Àü¸³¼±¾Ï.
  • radiation cancer
    ¹æ»ç¼± ¾Ï
  • radiation induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • recurrent cervical cancer
    Àç¹ß¼º ÀڱðæºÎ¾Ï
  • renal cancer
    ½Å¾Ï(ãìäß)
  • absolute risk
    Àý´ëÀ§Çè
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • acceptable risk
    ¿ëÀÎÀ§Çèµµ, ¼ö¿ëÀ§Çèµµ
  • anesthetic risk
    ¸¶ÃëÀ§Çèµµ.
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • high risk infant
    °íÀ§Ç輺 ¿µ¾Æ.
  • physical hazard =p. risk
    ½ÅüÀû À§Çè (ÊÙËøËôÌ´).
  • physical risk =physical hazard
    ½ÅüÀû À§Çè(µµ)(ËàÌ§ËøËô̴̬)
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼± À§Çè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼± À§Çè
  • radiation risk coeffecient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • recurrence risk
    Àç¹ßÀ§Çè
  • relative risk
    ºñ±³À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ(ËÓË´Ëô̴̬).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • risk factor
    À§ÇèÀÎÀÚ
  • risk factors
  • risk management
    À§Çè°ü¸®.
  • risk-benefit analysis
    À§Çè-À̵æºÐ¼®
  • surgical risk
    ¼ö¼úÀ§Çèµµ(¼ö¼úÀ§ÇèŹ).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • ascending colon
    ¿À¸§ÁÖ¸§Ã¢ÀÚ ¿À¸§°áÀå
  • ascending colon
    ¿À¸§ÁÖ¸§Ã¢ÀÚ
  • colon
    °áÀå(Ì¿íó).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cancer
    ¾Ï
  • cancer in situ
    »óÇdz»¾Ï, ÀνÃÅõ¾Ï
  • early gastric cancer
    Á¶±âÀ§¾Ï
  • mammary cancer
    À¯¾Ï
  • ovarian cancer
    ³­¼Ò¾Ï
  • polypoid cancer
    Æú¸³¾ç¾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • radiation induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • skin cancer
    ÇǺξÏ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
DCC day care center; detected in colon cancer; dextran-coated charcoal; diameter of cylindrical collimat...
HSSCC hereditary site-specific colon cancer
LSC late systolic click; left side colon cancer; left subclavian; lichen simplex chronicus; liquid scint...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ARR Absolute risk reduction
aRR Adjusted relative risk
AAR Area at risk
AR At-Risk
ARIC Atherosclerosis Risk In Communities
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • risk factor
    À§Çè ¿äÀÎ, À§Çè ¿ä¼Ò, À§Çè ÀÎÀÚ
    °³ÀÎÀ̳ª ´Üü°¡ ÁúȯÀ̳ª Àå¾Ö¿¡ °É¸®±â ½±°Ô ÇÏ´Â ¿øÀÎÀÌ µÇ´Â ¿ä¼Ò·Î¼­ ¹Î°¨ÇÑ »ç¶÷µé¿¡¼­ ¹ß»ý ºóµµ¿Í Á¤µµ¸¦ Áõ°¡½ÃŲ´Ù.
  • risk management
    ¼úÀÚÀÇ ¾ÈÀü ¼öÄ¢
  • risk principle
    À§Çèµµ ¿ø¸®
  • adneral cancer
    ºÎ½Å Á¾¾ç
  • adrenal cancer
    ºÎ½Å ¾ÏÁ¾
    ºÎ½Å ÇÇÁú Á¾¾ç¿¡´Â ¾Ëµµ½ºÅ×·ÐÁõ, Äí½Ì ÁõÈıº, ºÎ½Å ¼º±â ÁõÈıºÀÌ, ºÎ½Å ¼öÁú Á¾¾ç¿¡´Â °¥»ö ¼¼Æ÷ÁõÀÌ ÀÖ´Ù. Á¾¾ç¿¡¼­ ºÐºñµÇ´Â È£¸£¸ó¿¡ µû¶ó Áõ»óÀÌ ´Ù¸£´Ù.
  • anal cancer
    Ç×¹® ¾Ï
  • bladder cancer
    ¹æ±¤ ¾Ï
  • breast cancer
    À¯¹æ ¾Ï
  • cancer aquaticus
    ¼ö¾Ï, ±«Àú¼º ±¸³»¿°
  • cancer cell
    ¾Ï ¼¼Æ÷
    Á¤»óÀÎ Á¶Á÷ ¼¼Æ÷°¡ ¾î¶² ¿øÀÎÀ¸·Î ¹«Á¦ÇÑ Áõ½ÄÇÏ¿© ±× »ýüÀÇ »ýȰÇö»óÀ̳ª ÁÖÀ§ÀÇ Á¶Á÷ »óÅ µî¿¡ °ü°è¾øÀÌ ±Þ¼ÓÇÑ ¹ßÀ°À» °è¼ÓÇÏ¿© ¸¶Ä§³»´Â »ý¸íÀ» ²÷°Ô ÇÏ´Â ¾Ç¼ºÀÇ ½Å»ý¹°À̶ó°íµµ º¼ ¼ö ÀÖ´Â ¼¼Æ÷. ¼¼Æ÷ÇÐÀûÀ¸·Î º¸¸é ±× ¸ð¾çÀ̳ª Å©±â°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ´Ù¼Ò º¯È­µÇ¾î ÀÖ´Ù. Áï, ÇÙÀº ¿°»öü°¡ ¸¹°í, ÇÙÀÇ ¿øÇüÁú¿¡ ´ëÇÑ ºñ°¡ Å©¸ç, ÇÙ¼Òü¸¦ °¡Áö°í, ÀÚÁÖ ÇÙ ºÐ¿­»óÀ» ³ªÅ¸³½´Ù. À̰ÍÀ» ÀÌÇü¼ºÀ̶ó°í ÇÑ´Ù. ÀÌÇü¼ºÀÌ °­ÇÑ °ÍÀÌ ¾Ï ¼¼Æ÷ÀÇ Æ¯Â¡ÀÌ´Ù. À̰ÍÀ» ÀÌ¿ëÇÑ °ÍÀÌ ¼¼Æ÷ÁøÀ̸ç, À§¾Ï µî ¸ðµç ¾ÏÀÇ Á¶±â Áø´Ü¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ´Ù. Á¤»ó ¼¼Æ÷°¡ ¾î¶»°Ô ÇØ¼­ ¾Ï ¼¼Æ÷·Î º¯Çϴ°¡´Â ºÒ¸í·áÇÑ Á¡ÀÌ ¸¹Áö¸¸, È÷¸£È¿ÀÇ Àڱؼ³Àº À¯¸íÇÏ´Ù. À̰ÍÀº È­ÇÐÀû, ±â°èÀû, ¹°¸®Àû µîÀÇ ¸¸¼º ÀÚ±ØÀÌ ÀÛ¿ëÇÏ´Â °÷¿¡ ¾ÏÀÌ ¹ß»ýÇÑ´Ù´Â ¼³ÀÌ´Ù. ¹ÙÀÌ·¯½º¿ÍÀÇ °ü°èµµ ±Ù³â¿¡ ÁÖ¸ñÀ» ²ø¾î, F.P. ¶ó¿ì½ºÀÇ ´ßÀÇ À°Á¾ ¹ÙÀÌ·¯½º³ª R.E. ¼îÇÁÀÇ Åä³¢ÀÇ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â À¯¸íÇÏÁö¸¸, Àΰ£ÀÇ ¾Ï°ú È®½ÇÇÏ°Ô °ü°è¸¦ °®´Â ¹ÙÀÌ·¯½º´Â ¾ÆÁ÷ ¹ß°ßÇÏÁö ¸øÇϰí ÀÖ´Ù. ¾Ï ¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿Í ´Ù¸¥ Á¡Àº ÀÚÀ²ÀûÀ¸·Î Áõ½ÄÇϰí ÁÖÀ§ÀÇ Á¶Á÷À» ÆÄ±«ÇÏ¿© ħÀ±¼ºÀ¸·Î ¹ßÀ°ÇÏ´Â °Í, ¾Ï ¼¼Æ÷°¡ À¯¸®µÇ¾î ¸²ÇÁÇ༺, Ç÷Ç༺À¸·Î ¿ø°Ý Àå±â¿¡ ÀüÀÌÇÏ´Â °Í, ÆÄÁ¾À̶ó ÇÏ¿© º¹°­³»³ª Èä°­³»ÀÇ Àå±âÀÇ ¾Ï¿¡¼­´Â ¾Ï ¼¼Æ÷°¡ À帷¿¡ µµ´ÞÇÏ¸é º¹¸·À̳ª È丷¿¡ ºÎÂøÇÏ¿© ¹ßÀ°À» °è¼ÓÇÏ´Â °Í µîÀÌ´Ù. ÀÌ·± Ư¼º ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á°¡ º¹ÀâÇØÁö°í Àç¹ßµÇ±â ½±´Ù. µû¶ó¼­ ¾ÏÀ» °íÄ¡·Á¸é ¾Ï ¼¼Æ÷°¡ ÀÌ·± Ư¼ºÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ´Â Á¶±â¿¡ ¹ß°ß, Ä¡·áÇØ¾ß ÇÑ´Ù.
  • cancer en cuirasse
    °©¿Ê ¾Ï, Àå°© ¾Ï, Æ÷ÇÇ ¾Ï
    ÈäºÎ ÇǺο¡ ÀÚÁÖ ¹ß»ýÇÏ´Â ¾ÏÁ¾.
  • cancer nest
    ¾Ï¼Ò
    ¾Ï ¹ßÀ°ºÎ¿¡¼­ º¼ ¼ö ÀÖ´Â ±¸½É¼ºÀ¸·Î ¹è¿­µÈ ¾Ï ¼¼Æ÷ÀÇ µ¢¾î¸®.
  • cancer suppressor gene
    ¾Ï ¾ïÁ¦ À¯ÀüÀÚ
  • esophageal cancer
    ½Äµµ ¾Ï
  • head and neck cancer
    µÎ°æºÎ ¾Ï
    ¸Ó¸®¿Í ¸ñ ºÎÀ§¿¡ »ý±â´Â ¾Ï.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
risk factor <statistics> A clearly defined occurrence or characteristic that has been associated with the increased rate of a subsequently occurring disease.
(14 Oct 1997)
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
risk management The process of minimizing risk to an organization by developing systems to identify and analyze potential hazards to prevent accidents, injuries, and other adverse occurrences, and by attempting to handle events and incidents which do occur in such a manner that their effect and cost are minimised. Effective risk management has its greatest benefits in application to insurance in order to avert or minimise financial liability.
(12 Dec 1998)
risk of recurrence In medical genetics, the chance that a genetic (inherited) disease present in a family will recur in that family. The concept in general medicine means the chance that an illness we come back again.
(12 Dec 1998)
risk patient Patient who is at risk, because of his/her behaviour or because of the type of person he/she is.
(18 Nov 1997)
risk reduction Techniques used to reduce your chances of getting a certain cancer. For example: reducing your dietary fat may help prevent breast cancer.
(09 Oct 1997)
risk-taking Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviours whose outcomes may present a risk to the individual or to those associated with him or her.
(12 Dec 1998)
competing risk An event that removes a subject from being at risk for an outcome under investigation.
(05 Mar 2000)
pregnancy, high-risk Pregnancy in which the mother and/or foetus are at greater than normal risk of morbidity or mortality. Causes include lack of adequate prenatal care, previous obstetrical history, pre-existing maternal disease or pregnancy-induced disease, and multiple gestation, as well as advanced maternal age.
(12 Dec 1998)
health risk assessment Method of describing an individual's chance of falling ill or dying of a specified condition, based on actuarial calculations that allow for known exposure to risk; expressed as expected age at which death or disease will occur, and intended as a way of drawing an individual's attention to the probable consequences of risk behaviour.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
empiric risk The chance that a disease will occur in a family based upon experience (past history, medical records, etc.) rather than theory.
(12 Dec 1998)
adenomatous colon polyps <radiology> Probability of malignancy by size and type Size (cm) less than 1 1-2 greater than 2 --------------------------- tubular 1% 10% 34% mixed (TV) 4% 9% 45% villous 10% 10% 54%, most colon polyps (90%) are hyperplastic (size less than 5 mm)
(12 Dec 1998)
arterial arches of colon Anastomosing branches of the colic arteries that form arch's in the mesocolon from which the walls of the colon are supplied.
See: marginal artery of colon.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • risk manager
    º¸Çè ´ã´ç ÀÓÁ÷¿ø
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
  • risk-money
    ºÎÁ·±Ý º¸»ó ¼ö´ç(ÀºÇà µî¿¡¼­ Ãâ³³°è¿ø¿¡°Ô ÁÖ´Â)
  • security risk
    (Ä¡¾È»óÀÇ)À§Çè Àι°
  • war risk insurance
    ÀüÀï º¸Çè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á